Thymos Health
Your Sjögren's Journey

Still dry.
Still exhausted. Still no approved treatment.
Still searching for answers.

You're not alone. This is how Sjögren's disease is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

0.1–0.5% of the population is affected, primarily women over 50.1
5.98 years is the average diagnostic delay (median 2 years).2
0 FDA-approved systemic therapies exist for Sjögren's disease today.3
5–10% of patients go on to develop B-cell lymphoma.4

How Sjögren's is typically treated

There are no FDA-approved drugs for Sjögren. Every drug prescribed is used off-label, despite the evidence often weaker than patients assume.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your doctor recommends Artificial Tears & Saliva Substitutes
OTC lubricating eye drops, saliva substitutes, punctal plugs — symptom management only
What your doctor says
"Let's start with artificial tears and saliva substitutes to manage the dryness in your eyes and mouth."
Low risk, widely available over-the-counter
Addresses dryness symptoms only — no effect on systemic disease
Often used indefinitely alongside every later step
Annual cost before insurance ~$200–$900
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Dryness persists, systemic symptoms (fatigue, joint pain) emerge
Step 2: Your rheumatologist adds Hydroxychloroquine
Plaquenil — 200–400mg/day, the most commonly prescribed systemic agent for Sjögren's
What your doctor says
"Hydroxychloroquine is our go-to systemic option for Sjögren's — it's well tolerated and helps with fatigue and joint symptoms for many patients."
A 2-year randomized placebo-controlled trial found no clinical benefit5
Widely prescribed despite a mixed evidence base
Annual cost before insurance (generic) ~$150–$500
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Progressive disease impacting the lungs, nerves, and joint damage
Step 3: For systemic disease, off-label Rituximab or Other Off-Label Biologic
Rituximab (anti-CD20), belimumab, or other immunomodulators — none FDA-approved for Sjögren's
What your doctor says
"Let's try rituximab. It's not officially approved for Sjögren's, but many rheumatologists use it for systemic symptoms."
No biologic FDA approved to effectively treat Sjögren's3
Annual cost before insurance ~$15,000–$30,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
What years of “it's just dryness” can miss Systemic & Lymphoproliferative Complications
Interstitial lung disease, peripheral neuropathy, and a meaningfully elevated lymphoma risk — often under-monitored while treatment stays focused on dryness
What Your Doctor says
"Your dry eyes and mouth are the main things we track. If something else comes up systemically, we'll address it as it happens."
5.98 yr
Average diagnostic latency (median 2 years)2
5–10%
Lifetime risk of developing B-cell lymphoma4
1.6×
Higher all-cause annual healthcare costs vs. matched controls9
0
FDA-approved systemic disease-modifying therapies8
The evidence gap, by the numbers
HCQ 2-year double-blind crossover trial result No clinical benefit shown
Rituximab TRACTISS trial (primary endpoints) Not met
Ianalumab phase 3 trials (2025) Both met primary endpoint
FDA-approved systemic therapies as of today None
What that gap means for patients
🧪 The most commonly prescribed drug has thin randomized evidence behind it. A dedicated 2-year, placebo-controlled, double-blind crossover trial of hydroxychloroquine found no clinically meaningful benefit for the classic symptoms of Sjögren's, despite it remaining the default systemic prescription.5
💊 Even the most-used biologic failed its defining trial. TRACTISS, a UK multicenter randomized trial of rituximab in high-burden patients, did not show improvement in dryness or fatigue — yet rituximab remains the most widely used biologic for extraglandular Sjögren's.7
🧬 Real disease-modifying options are only now emerging. Ianalumab became the first agent to meet its primary endpoint in two global phase 3 trials in 2025 — the first positive systemic Sjögren's trials of this scale, arriving decades after diagnosis criteria were established.10
🩺 Cost and disease burden climb even without a lymphoma diagnosis. Patients with extraglandular disease incur nearly 3× the annual costs of patients with glandular (dryness-only) disease, and Sjögren's costs already approach those of rheumatoid arthritis even before RA's biologic era.9
⚠ “No approved treatment” is not the same as “nothing more can be done”
The absence of an FDA-approved systemic therapy has meant symptom management gets most of the attention, while systemic surveillance — for lung, nerve, and lymphoproliferative involvement — is left inconsistent. That gap, not the dryness itself, is where the most serious long-term risk sits.

What Sjögren's is really costing you

With no approved systemic drug, much of the true cost of Sjögren's shows up as fatigue-driven missed work and the compounding effect of symptoms that are treated piecemeal rather than as one disease.

Based on your journey above–adjust the numbers to match your situation.
Work days affected by fatigue/pain/dryness in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of Sjögren's $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Fatigue and pain are the most disabling Sjögren's symptoms day-to-day, even when dryness itself is well controlled. Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
If your care reaches the last phase of this journey — Rituximab or Other Off-Label Biologic
$0
Projected patient out-of-pocket cost for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).

What your insurer is paying

Because no drug carries an official Sjögren's indication, most treatment is billed under off-label use or adjacent diagnoses — making the true cost of this disease harder for payers to see clearly, even as it approaches rheumatoid arthritis spend level.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your Sjögren's each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your Sjögren's care $0
Off-label systemic/biologic drug spend (payer portion)
~80% of net price after patient coinsurance; nearly all systemic Sjögren's prescribing today is off-label
$0
Medical costs (rheumatology, ophthalmology, dental, labs)
Sjögren's requires coordination across more specialties than most autoimmune diseases — dental costs alone are significantly elevated
~$6,500
Do you have extraglandular involvement (lung, nerve, or lymph node)?
Patients with extraglandular disease incur roughly 2.9× the average annual cost of patients with glandular-only disease
Sjögren's patients incur nearly double the annual healthcare costs of matched individuals without the disease — with dental costs a uniquely elevated line item.
Payer cost projection if care reaches the last phase of this journey — Rituximab or Other Off-Label Biologic
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ The cost of having no approved drug
With zero FDA-approved systemic therapies, spend gets distributed across many off-label prescriptions and specialist visits rather than concentrated in one clear pharmacy line — which can make Sjögren's look artificially inexpensive on a claims summary even as total cost of care approaches RA levels.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented experience for patients managed with today's off-label, symptom-first standard of care.

Based on peer-reviewed clinical data
Long-term outcomes for Sjögren's patients on today's standard of care
⏳
5.98 yr average delay before diagnosis, during which systemic involvement can go unmonitored2
🧬
5–10% lifetime risk of developing B-cell lymphoma, the disease's most serious long-term complication4
💊
0 → 1 FDA-approved systemic therapies today, with ianalumab the first agent to meet phase 3 primary endpoints (2025)10
🦷
1.6–2.9× higher annual healthcare costs versus matched controls, rising further with extraglandular involvement9
✦ A different journey exists

Thymos Health offers another way

Conventional Sjögren's care treats dry eyes and dry mouth as the disease, with systemic surveillance left inconsistent. Thymos goes further – synthesizing your antibody profile, organ-system symptoms, and treatment history to build a coordinated surveillance and treatment plan, not just a prescription for artificial tears.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Proteins linked to type II interferon response in Sjögren's disease. PMC, 2025. Primary Sjögren's disease prevalence 0.1–0.5% in the general population, primarily affecting women above age 50.
PMC: PMC12575357
[2] Impact of time to diagnosis in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2024. Average diagnostic latency 5.98 years; median 2 years.
Source: clinexprheumatol.org
[3] Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. ScienceDirect, 2026. Rituximab, although widely used off-label, has not been FDA-approved for Sjögren's disease; described as a disease “with very limited treatment options and an established unmet need.”
Source: sciencedirect.com
[4] Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome. PMC, propensity-matched landmark analysis. Background literature cites a pooled relative risk indicating substantially elevated lymphoma risk in pSS; commonly cited estimate of lifetime B-cell lymphoma risk is 5–10%.
PMC: PMC5655212
[5] Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Annals of the Rheumatic Diseases / PubMed. No beneficial clinical effect of hydroxychloroquine 400mg/day over 12 months was shown for symptoms and signs of primary Sjögren's syndrome, despite improvement in hyperglobulinemia and ESR/IgM.
PMID: 8323383
[6] Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren's syndrome: a real-world study. PubMed, 2025 (n=1,089). Higher-dose HCQ (300–400mg/day or >5mg/kg) was associated with higher response rates in specific subgroups, particularly younger, seropositive patients without diabetes/hypertension.
PMID: 40751894
[7] Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. PMC, 2023. TRACTISS (UK multicenter, double-blind RCT, n=133): rituximab did not improve dryness, fatigue, or brain fog in the majority of high-symptom-burden patients, despite remaining the most widely used off-label biologic.
PMC: PMC10330372
[8] Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease. Novartis press release, 2025, describing Sjögren's disease as having “very limited treatment options and an established unmet need,” with no approved systemic therapies at the time.
Source: novartis.com
[9] Clinical and Cost Burden of Primary Sjögren's Syndrome: Descriptive Analysis Using a US Administrative Claims Database. PMC, 2018 (n=12,717). Patients with extraglandular manifestations incurred 2.9× greater average annual costs than patients with glandular-only disease; a comparative UK study found Sjögren's total direct medical costs approaching those of rheumatoid arthritis.
PMC: PMC9090467
[10] Ianalumab significantly improved disease activity and symptoms in patients with Sjögren's disease, phase 3 trials show. Cleveland Clinic Journal of Medicine, 2025, reporting NEPTUNUS-1 and NEPTUNUS-2 phase 3 results presented at ACR 2025 — the first positive large-scale systemic Sjögren's disease trials.
Source: ccjm.org